Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
52 hedge funds and large institutions have $480M invested in Odonate Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 4 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
4% more funds holding
Funds holding: 50 → 52 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less capital invested
Capital invested by funds: $516M → $480M (-$35.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$28.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.11M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$1.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$770K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.04M |
| 2 |
BC
Broadfin Capital
New York
|
-$2.06M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.12M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.02M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$462K |
ODT Hedge Fund Activity: Q3 2018 in Review
52 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q3 2018, worth a combined $480M — down 7% from $516M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ODT positions and 4 closed out — a net gain of 2 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $28.2M. The largest seller was Fidelity Investments, cutting an estimated $7.04M.
- 52 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q3 2018, up from 50 in Q2 2018.
- Funds reported $480M of Odonate Therapeutics, Inc. Common Stock stock for Q3 2018, down 7% quarter-over-quarter.
- 6 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q3 2018 and 4 closed out, a net change of +2 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q3 2018 was Tang Capital Management, an estimated $28.2M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $7.04M sold.
Based on aggregated 13F filings for Q3 2018.